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INTRODUCTION
Among the general population, it has been assumed that
an average of 150 to 250  g of lead is ingested through food
each day, five to ten percent of which is absorbed (1, 2). The
other sources for lead poisoning may be lead-soldered kettles,
cans, and lead-glazed pottery, which release lead when acidic
fluids are stored or cooked in them (2).
The lead in blood is equilibrated with that of lead in tis-
sues, including many potential target organs such as the
brain and kidney. The kinetic model of lead in the body is
not defined well, but usually it consists of two pools: in the
blood and in the skeleton, which may be divided further into
labile and deep pools (3). The kidney is the main organ excre-
ting lead from pool. Thus, lead burdens have a tendency to
be accumulated in the patients with renal failure (4). 
The skeleton acts as a reservoir of lead, and it may be mobi-
lized by physiological and pathological states including preg-
nancy, lactation, and osteoporosis (5, 6). In patients with end-
stage renal disease (ESRD), hyperparathyroidism, abnormal
vitamin D metabolism, and consequent osteoporosis have
frequently been observed (7). Taken together with the lack
of renal excretion and stimulated bone resorption, the blood
level of lead seems to increase in ESRD and may aggravate
uremic symptoms such as peripheral neuropathy and anemia.
The classic clinical manifestations of industrial lead poison-
ing include colic, anemia, peripheral neuropathy, encephalopa-
thy, renal impairment, hypertension, and reproductive dis-
ability (8). More recently, recognition has become widespread
that, in addition to its clinically evident toxicity, lead also
causes a spectrum of adverse effects at levels of exposure insuf-
ficient to produce obvious signs and symptoms. The premise
underlying this recognition is that there exist asymptotic,
subclinical counterparts. Thus, clinically obvious manifesta-
tions of lead poisoning such as anemia, peripheral neuropa-
thy, and renal failure lie at the upper end of the range of toxi-
city, while such covert effects as impaired synthesis of heme,
altered excretion of uric acid, and slowed nerve conduction
are their subclinical correlate (9). 
Diseases of the peripheral nervous system are among the
most prevalent neurologic conditions in ESRD (10). Nonethe-
less, differential diagnosis of peripheral nerve disease is chal-
lenging because the catalogue of disorders that can produce
neuropathies is extensive in ESRD. First of all, many patients
with renal failure develop electrophysiologic evidence of
peripheral neuropathy (11). The primary pathophysiology
of uremic neuropathy remains unknown. According to one
theory (12), some slowly dializable substances of intermedi-
ate molecular weight alter the peripheral nerve in some man-
ner, resulting in axonal dysfunction and eventually degener-
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Influence of Blood Lead Concentration on the Nerve Conduction
Velocity in Patients with End-Stage Renal Disease
Diseases of the peripheral nervous system are the most prevalent in patients with
end-stage renal disease (ESRD). Although increased blood levels of lead in ESRD
have been reported, the role of lead remains to be elucidated. The purpose of this
study was to determine the connection of blood lead concentration with peripheral
nerve conduction velocity. One hundred ninety-eight healthy subjects (control group)
and 68 patients with ESRD undergoing hemodialysis (ESRD group) were enrolled.
Nerve conduction was measured within two hours after hemodialysis. Orthodromic
sensory nerve action potentials and compound muscle action potentials were record-
ed on the median, ulnar, and radial nerves. Hemoglobin-corrected blood lead was
significantly higher in ESRD patients than in controls (9.1± ±2.8  g/dL vs. 5.9± ±2.3
g/dL, p<0.001). 32.4% of 68 ESRD patients with diabetes mellitus were significantly
related to poorer motor and sensory nerve conduction velocity (p<0.001). However,
blood lead was not a significant predictor of the nerve conduction velocity (p>0.05).
Our result suggested that even though the blood lead levels were high in ESRD,
they were not associated with the decline of peripheral nerve function. Diabetes
mellitus is a primary independent risk of neuropathy in ESRD patients.
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ation. The other causes of the peripheral neuropathy in ESRD
are diabetes mellitus, pharmaceutic neurotoxins, alcohol-nutri-
tional neuropathy, and industrial and environmental neuro-
toxins such as lead, mercury, arsenic, and thallium. 
Although many investigators have described increased
blood levels of lead in renal failure patients (13-16), the role
of lead on the clinical characteristics remains to be elucidat-
ed. The purpose of this study is to determine the blood con-
centration of lead in patients with end-stage renal disease
and to validate the relation with peripheral motor and sen-
sory nerve conduction velocity as clinical correlates.
MATERIALS AND METHODS 
Subjects
One hundred ninety-eight healthy subjects (control group,
147 men, 51 women; mean age, 43.2±11.5 yr) and 68
patients with ESRD undergoing hemodialysis (ESRD group,
31 men, 37 women; mean age, 50.1±12.3 yr) were enrolled
for the blood lead measurement. The control group com-
prised healthy volunteers recruited during a regular physi-
cal examination at Soonchunhyang University Health Pro-
motion Center (Cheonan, Korea). Blood samples for lead con-
centration were drawn from the antecubital vein in the morn-
ing after overnight fasting. 
The ESRD patients were undergoing regular hemodialysis
eight to twelve hours weekly using a cellulose acetate hollow-
fiber dialyser (surface area 1.2 m2; Gambro, Sweden, or Bax-
ter, U.S.A.) at a hemodialysis unit of the Soonchunhyang
Cheonan Hospital. In order to avoid any influence of carpal
tunnel syndrome and/or ischemic neuropathy on the result
of peripheral nerve conduction study, any patients who had
vascular access on the right arm and had past histories of cere-
brovascular disease, with or without hemiparesis, were ex-
cluded from this study. Among 124 ESRD patients on hemo-
dialysis, 68 cases were consistent with these terms. 
This study was approved by the Institutional Review Board
of Soonchunhyang Cheonan Hospital (Cheonan, Korea), and
all human subjects provided written informed consent
Measurement of nerve conduction velocity
Nerve conduction was measured within two hours after
hemodialysis. The upper limb temperatures were maintained
above 34℃ and lower limb temperatures above 32℃, using
hot packs when necessary. Orthodromic sensory nerve action
potentials and compound muscle action potentials were
recorded in response to supramaximal constant-voltage stim-
ulation (duration=0.1 msec; sensory=20 mA, motor=25-35
mA). Stimuli were delivered from a bipolar stimulator; stim-
ulating electrodes were 0.8 cm in diameter, and their centers
separated by 1.8 cm. Motor and sensory responses were record-
ed with 0.8 cm disk electrodes. The amplifier band pass was
2-10.000 Hz for all nerve conduction study. A Dantec Key-
point version 2.0 electrodiagnostic system (Dantec Com,
Skovlunde, Denmark) was employed. Studies were performed
by two physicians among the authors and were assisted by a
technologist. 
For excluding idiopathic carpal tunnel syndrome, which
could also be caused by diabetes and uremia, we included
both the motor conduction study in the wrist-elbow segment
of the median and ulnar nerves and the motor and sensory
conduction studies in the radial nerve. Results were com-
pared with age-specific normative data obtained in the same
laboratory.
Measurement of blood lead concentration
Blood samples for lead level, CBC, and general chemistry
were drawn from a venous line at the beginning of hemodial-
ysis. Blood lead level was analyzed in duplicate with a Zee-
man background-corrected atomic absorption spectropho-
tometer (Hitachi Z-8100, Japan) with NIOSH’s standard
addition method (17) at Soonchunhyang University Insti-
tute of Industrial Medicine, a certified reference laboratory
for lead in Korea. 
Statistical analysis
Data were presented as a mean (SD) for continuous vari-
ables and frequency (%) for categorical variables. Pearson’s
correlation was applied between outcomes and covariates.
Multiple linear regression was used to determine associa-
tions between blood lead and nerve conduction tests, adjust-
ing for potential confounders. For easy presentation of results,
the final regression models were selected with the same set
of confounding variables (i.e., age, sex, duration of hemodial-
ysis, Kt/V, and protein catabolic rate). All models were evalu-
ated for violation of the assumptions of linear regression. A
value of p<0.05 was considered statistically significant, and
all statistical analysis was performed using a Stata program
(Stata Release 5, College Station, Texas, U.S.A.).
RESULTS
In the control group, mean systolic and diastolic blood
pressure were 120.5±17.8 mmHg and 77.1±12.9 mmHg,
respectively. Hemoglobin and hematocrit were 14.5±2.2
mg/dL and 42.5±4.2%. Serum calcium and phosphorus
were 9.9±0.39 mg/dL and 3.89±0.59 mg/dL (Table 1).
In ESRD group, the median duration of hemodialysis was
42.5 months (range; 1 to 210 months). The causes of renal
disease were diabetes mellitus (n=22), hypertension (n=20),
polycystic kidney disease (n=1), glomerulonephritis (n=20),
and unknown factors (n=7). Kt/V was 1.30±0.27. Normal-292 Y.-S. Kim, J.-H. Park, J.-R. Hong, et al.
ized protein catabolic rate (nPCR) was 1.2±0.2. Mean sys-
tolic blood pressure was 142.2±15.5 mmHg, and mean
diastolic blood pressure was 85.4±9.9 mmHg. Sixty two
of 68 patients have had anti-hypertensive medications. Sev-
enteen cases (25%) were current smokers and 8 patients
(11.8%) were regular drinkers (Table 2). The mean serum
albumin level was 3.7±0.4 g/dL. Hemoglobin was 9.1±
1.1 mg/dL and hematocrit was 26.2±3.1%. Serum calci-
um and phosphorus were 9.34±1.07 mg/dL and 5.13±
1.61 mg/dL, respectively.
Blood lead levels were corrected by hemoglobin (15 mg/
dL) in both groups, and compared. After the correction, blood
lead levels were significantly higher in the ESRD group than in
control group (p<0.001). All other study variables were sig-
nificantly different between the groups (p<0.001) (Table 1).
Summary of nerve conduction tests is displayed in Fig. 1. Blood
lead was significantly correlated with duration of hemodial-
ysis (p<0.05) (Table 3). However, other study variables were
not related to blood lead. Also, motor or sensory nerve con-
duction velocity did not show significant correlation with
blood lead in ESRD patients (Table 4). The positive correla-
tion was observed between nutritional marker, nPCR, and
ulnar motor nerve conduction velocity. Also, the positive
Variable
Controls (n=198)
Mean±SD
Patients (n=68)
Mean±SD
p-value
Age (yr) 43.2±11.5 50.1±12.3 <0.001
Sex, male (%) 147 (74.2) 31 (45.6) <0.001
Blood lead ( g/dL) 5.9±2.3 9.1±2.8 <0.001
Systolic blood  120.5±17.8 142.2±15.3 <0.001
pressure (mmHg)
Diastolic blood  77.1±12.9 85.4±9.9 <0.001
pressure (mmHg)
Hemoglobin (mg/dL) 14.5±1.2 9.1±1.1 <0.001
Hematocrit (%) 42.5±4.2 26.2±3.1 <0.001
Serum calcium (mg/dL) 9.90±0.39 9.34±1.07 <0.001
Serum phosphorus (mg/dL) 3.89±0.59 5.13±1.61 <0.001
Table 1. Comparison of general characteristics between con-
trols and patients with end-stage renal failure
Variable Mean±SD Range
Duration of dialysis (yr) 3.6±3.4 0-12.0
Antihypertensive medication (%) 55 (90.9)
Diabetes mellitus (%) 22 (32.4)
Albumin (g/dL) 3.7±0.4 2.0-4.4
Normalized protein catabolic rate 1.03±0.38 0.43-3.1
Kt/V 1.30±0.27 0.86-2.06
Current smoker (%) 17 (25.0)
Regular drinker (%) 8 (11.8)
Table 2. Clinical parameters of patients (n=68) with end-stage
renal failure
Age Duration NPCR Kt/V Pb
Duration 0.12
NPCR -0.12 0.25*
Kt-V -0.11 0.19 0.19
Pb -0.10 0.25* 0.13 -0.02
Hemoglobin 0.02 0.20 0.15 0.11 0.30*
Table 3. Correlation matrix between selected covariates in 68
patients with end-stage renal failure
*p<0.05. Duration, duration of hemodialysis. NPCR, normalized protein
catabolic rate; Pb, hemoglobin corrected blood lead ( g/dL).
Age Function Nerve Duration NPCR Kt/V Pb
Motor Median -0.20 -0.06 -0.07 0.13 0.12
Ulnar 0.001 0.07 -0.07 0.04 0.30*
Radial 0.07 0.25* 0.12 0.14 0.16
Sensory Median -0.10 0.03 -0.10 0.04 0.09
Ulnar -0.03 0.09 -0.09 0.06 0.12
Radial -0.06 0.04 -0.06 0.25 0.11
Table 4. Correlation between selected covariates and nerve con-
duction test in 68 patients with end stage renal failure
*p<0.05. Duration, duration of hemodialysis. NPCR, normalized protein
catabolic rate; Pb, hemoglobin corrected blood lead ( g/dL).
Function Nerve
Blood lead ( g/dL)
Adjusted coefficient 
(p-value)
Diabetes mellitus 
(No vs. Yes)
Adjusted coefficient 
(p-value)
Motor Median 0.033 (0.883) -7.840 (<0.001)
Ulnar  0.057 (0.847) -8.821 (<0.001)
Radial 0.551 (0.303) -7.217 (0.010)
Sensory Median 0.314 (0.634) -21.788 (<0.001)
Ulnar 0.161 (0.828) -18.602 (<0.001)
Radial 0.511 (0.423) -17.062 (<0.001)
Table 5. Results of multiple linear regression of hemoglobin-cor-
rected blood lead and diabetes mellitus with each nerve conduc-
tion test in 68 patients with end-stage renal failure
*controlling for age, duration of hemodialysis, sex, KT-V, and protein
catabolic rate.
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Fig. 1. Box plots of nerve conduction tests in 68 patients with end-
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correlation was observed between duration and radial senso-
ry nerve conduction velocity.
In the final models, blood lead was not a significant pre-
dictor of poor nerve conduction velocity. Patients with dia-
betes mellitus showed significantly worse motor and senso-
ry function in all three nerves than those without diabetes
mellitus (p<0.01) (Table 5).
DISCUSSION
Lead poisoning may remain asymptomatic for many years.
Major forms of lead poisoning are lead colic, hypertension,
and neuropathy. On the other hand, minor symptoms are
common and variable: cramps, paresthesia, intermittent
pain in the limbs, chronic abdominal pain, and functional
digestive disturbances. It is not easy to define these symp-
toms in patients with ESRD because uremia itself may cause
of and/or aggravate these symptoms. Furthermore, chronic
lead poisoning may be a cause ESRD (18-21). The design of
our study does not enable us to discuss the role of lead over-
load in the onset of ESRD. Determination of such a relation-
ship would require epidemiological studies conducted accord-
ing to rigorous methodology. 
In our results, the blood lead levels were significantly
higher, almost twice that of the control group (9.1±2.8 g/
dL vs. 5.9±2.3  g/dL) in ESRD patients. However, con-
trary to our expectation, there was no correlation between
the blood lead levels and peripheral nerve conduction. Of
course, there are many factors influencing the peripheral nerve
conduction in ESRD. Approximately 60% of patients with
renal failure develop electrophysiologic evidence of periph-
eral neuropathy (22). The pathophysiology of uremic neuro-
pathy remains unknown. Some slowly dializable substances
of intermediate molecular weight have been proposed as
pathogens, resulting in axonal dysfunction and eventually
degeneration (12). With this point of view, heterogeneity of
adequacy in hemodialysis may influence the nerve conduc-
tion. But in our study, the Kt/V was 1.30±0.27, and there
was no correlation between Kt/V and peripheral nerve con-
duction. 
Another problem during the evaluation of peripheral nerve
conduction is the possibility of carpal tunnel syndrome in
patients with ESRD. It is well known that patients with
ESRD are apt to suffer from carpal tunnel syndrome (23-25),
which may mask the results of peripheral nerve conduction
study. The carpal tunnel syndrome is related to a small  2
microglobulin that normally is catabolized by the healthy
kidney (26, 27). This substance forms a type of amyloid
deposit throughout the body, with particularly adverse con-
sequences when it is deposited in the carpal tunnel about
the transverse carpal ligament. On the other hand, a profound
combined ischemic neuropathy, referred to as an ischemic
monomelic neuropathy, may result in patients with limb
ischemia secondary to shunt (22, 28). A significant combined
neuropathy may be associated with loss of sensation and mus-
cle weakness in the distal arm supplied by the shunted ves-
sels. In order to avoid any influence of carpal tunnel syndrome
and/or ischemic neuropathy on the result of our peripheral nerve
conduction study, we performed the motor conduction study
on the wrist-elbow segment of the median and ulnar nerves,
and the motor and sensory conduction studies on the radial
nerve in the right arm. Any patients who have vascular access
in the right arm were excluded from this study.
Alcohol and nutrition are also important factors in periph-
eral neuropathy in ESRD (22). In our results, both sensory
nerve action potentials and compound muscle action poten-
tials were significantly more suppressed in patients with
diabetes mellitus than in the non-diabetes mellitus group.
The nutritional markers of nPCR (1.03±0.38) and serum
albumin level (3.7±0.4 g/dL) were relatively homogenous
among the patients with hemodialysis. In our result, positive
correlation was observed between nPCR and ulnar motor
nerve conduction. But the other nerve was not correlated.
We guess that malnutrition is important factor about nerve
conduction in ESRD patient, but only decreased nPCR may
be no prognostic marker about nerve conduction.
The other causes of peripheral neuropathy in ESRD are
pharmaceutic neurotoxins and industrial and environmental
neurotoxins such as mercury, arsenic, and thallium (22). We
did not measure such metals. Further studies are needed for
evaluation of peripheral neuropathy in ESRD. 
Of course, there is a possibility that the blood lead levels
are not high enough to produce the neuropathy in ESRD
patients. In the peripheral nervous system, the motor axons
are the principal target of lead. Lead-induced pathologic
changes in these fibers include segmental demyelination and
axonal degeneration (29). Recent studies of the peripheral
nerves in persons exposed to lead have used electrophysio-
logic probes to determine whether lead causes covert abnor-
malities in function. They found slowed conduction in the
small motor fibers of the ulnar nerve to be the most sensitive
peripheral index of the neurotoxicity of lead and the ulnar
nerve conduction velocity was depressed at blood levels below
50  g/dL. In conjunction with this report, our result reveals
that, even though the blood lead levels were high in ESRD,
they were still below the level of inducing peripheral neuro-
pathy. 
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